340B Rebate Pilot: What Hospitals Need to Do Now Before Possible 2027 Launch

📋 Regulatory Action / Label Change HRSA's revised 340B rebate pilot is scheduled to begin January 1, 2027, and would fundamentally change how participating covered entities receive 340B savings on selected Medicare Drug Price Negotiation Program products. Rather than purchasing eligible drugs at discounted 340B prices, organizations would buy qualifying products at wholesale acquisition cost and later obtain manufacturer-paid rebates after submitting pharmacy and medical claims data. Covered entities will not know the operational details of manufacturer participation plans until September 24, leaving a relatively short preparation period. While litigation and congressional efforts could still alter the program, organizations are being advised to prepare for implementation rather than assume further delays or cancellation. Professional Impact Covered entities may need new workflows to identify eligible claims, submit rebate documentation, track payments, and reconcile rebates against drug purchases. Participating manufacturers must reimburse approved claims within 10 calendar days after receiving a complete submission. after receiving a complete submission. The pilot initially applies to selected drugs included in Medicare's Drug Price Negotiation Program lists for 2026 and 2027. Organizations may experience cash-flow pressure because drugs are purchased at full acquisition cost before rebate recovery. Pharmacy and medical claims data may need to be collected from multiple systems that are not currently designed for these reporting requirements. Existing 340B third-party administrators (TPAs) and technology vendors may require significant enhancements depending on final manufacturer reporting requirements. Uncertainty remains regarding whether manufacturers will utilize a common rebate portal or multiple reporting platforms. Action Items